{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T07:18:21Z","timestamp":1774509501565,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The SARS-CoV-2 Omicron variant has very high levels of transmission, is resistant to neutralization by authorized therapeutic human monoclonal antibodies (mAb) and is less sensitive to vaccine-mediated immunity. To provide additional therapies against Omicron, we isolated a mAb named P2G3 from a previously infected vaccinated donor and showed that it has picomolar-range neutralizing activity against Omicron BA.1, BA.1.1, BA.2 and all other variants tested. We solved the structure of P2G3 Fab in complex with the Omicron spike using cryo-electron microscopy at 3.04\u2009\u00c5 resolution to identify the P2G3 epitope as a Class 3 mAb that is different from mAb-binding spike epitopes reported previously. Using a SARS-CoV-2 Omicron monkey challenge model, we show that P2G3 alone, or in combination with P5C3 (a broadly active Class 1 mAb previously identified), confers complete prophylactic or therapeutic protection. Although we could select for SARS-CoV-2 mutants escaping neutralization by P2G3 or by P5C3 in vitro, they had low infectivity and \u2018escape\u2019 mutations are extremely rare in public sequence databases. We conclude that this combination of mAbs has potential as an anti-Omicron drug.<\/jats:p>","DOI":"10.1038\/s41564-022-01198-6","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T10:02:49Z","timestamp":1658743369000},"page":"1376-1389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9435-0110","authenticated-orcid":false,"given":"Craig","family":"Fenwick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-9977","authenticated-orcid":false,"given":"Priscilla","family":"Turelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongchun","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-7928","authenticated-orcid":false,"given":"Laurent","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-7597","authenticated-orcid":false,"given":"Kelvin","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Herate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Marlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Lana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Pellaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1558-5916","authenticated-orcid":false,"given":"Charl\u00e8ne","family":"Raclot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line","family":"Esteves-Leuenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9my","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flurin","family":"Fiscalini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-6313","authenticated-orcid":false,"given":"Nathalie","family":"Dereuddre-Bosquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Relouzat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-7312","authenticated-orcid":false,"given":"Rana","family":"Abdelnabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-4917","authenticated-orcid":false,"given":"Caroline S.","family":"Foo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0033-7514","authenticated-orcid":false,"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7537-1688","authenticated-orcid":false,"given":"Pieter","family":"Leyssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5549-6256","authenticated-orcid":false,"given":"Yves","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Pojer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1185-4592","authenticated-orcid":false,"given":"Henning","family":"Stahlberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"LeGrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3383-0401","authenticated-orcid":false,"given":"Didier","family":"Trono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-2721","authenticated-orcid":false,"given":"Giuseppe","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"1198_CR1","unstructured":"Weekly Epidemiological Update on COVID-19 - 18 January 2022 (WHO, 2022)."},{"key":"1198_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/gch2.1018","volume":"1","author":"S Elbe","year":"2017","unstructured":"Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID\u2019s innovative contribution to global health. Glob. Chall. 1, 33\u201346 (2017).","journal-title":"Glob. Chall."},{"key":"1198_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","volume":"603","author":"R Viana","year":"2022","unstructured":"Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679\u2013686 (2022).","journal-title":"Nature"},{"key":"1198_CR4","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","volume":"182","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell 182, 828\u2013842.e16 (2020).","journal-title":"Cell"},{"key":"1198_CR5","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042.e21 (2020).","journal-title":"Cell"},{"key":"1198_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"1198_CR7","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372\u20132383.e79 (2021).","journal-title":"Cell"},{"key":"1198_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553\u2013556 (2022).","journal-title":"Nature"},{"key":"1198_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"YW Cao","year":"2022","unstructured":"Cao, Y. W. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"1198_CR10","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","volume":"28","author":"LA VanBlargan","year":"2022","unstructured":"VanBlargan, L. A. et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. 28, 490\u2013495 (2022).","journal-title":"Nat. Med."},{"key":"1198_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2021).","journal-title":"Nature"},{"key":"1198_CR12","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1126\/science.abn7760","volume":"375","author":"D Mannar","year":"2022","unstructured":"Mannar, D. et al. SARS-CoV-2 Omicron variant: antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science 375, 760\u2013764 (2022).","journal-title":"Science"},{"key":"1198_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","volume":"602","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671\u2013675 (2021).","journal-title":"Nature"},{"key":"1198_CR14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622 (2021).","journal-title":"Nature"},{"key":"1198_CR15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med 27, 717\u2013726 (2021).","journal-title":"Nat. Med"},{"key":"1198_CR16","doi-asserted-by":"publisher","first-page":"eabi8452","DOI":"10.1126\/scitranslmed.abi8452","volume":"13","author":"C Fenwick","year":"2021","unstructured":"Fenwick, C. et al. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Sci. Transl. Med. 13, eabi8452 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1198_CR17","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1126\/science.abd0831","volume":"369","author":"A Baum","year":"2020","unstructured":"Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014\u20131018 (2020).","journal-title":"Science"},{"key":"1198_CR18","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41564-021-00972-2","volume":"6","author":"J Dong","year":"2021","unstructured":"Dong, J. et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat. Microbiol. 6, 1233\u20131244 (2021).","journal-title":"Nat. Microbiol."},{"key":"1198_CR19","doi-asserted-by":"publisher","unstructured":"Rappazzo, C. G. et al. An engineered antibody with broad protective efficacy in murine models of SARS and COVID-19. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.11.17.385500 (2020).","DOI":"10.1101\/2020.11.17.385500"},{"key":"1198_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"1198_CR21","doi-asserted-by":"publisher","first-page":"109814","DOI":"10.1016\/j.celrep.2021.109814","volume":"37","author":"C Fenwick","year":"2021","unstructured":"Fenwick, C. et al. A highly potent antibody effective against SARS-CoV-2 variants of concern. Cell Rep. 37, 109814 (2021).","journal-title":"Cell Rep."},{"key":"1198_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41586-021-03925-1","volume":"598","author":"FA Lempp","year":"2021","unstructured":"Lempp, F. A. et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature 598, 342\u2013347 (2021).","journal-title":"Nature"},{"key":"1198_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-021-04017-w","volume":"599","author":"R Yamin","year":"2021","unstructured":"Yamin, R. et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature 599, 465\u2013470 (2021).","journal-title":"Nature"},{"key":"1198_CR24","doi-asserted-by":"publisher","first-page":"e20201993","DOI":"10.1084\/jem.20201993","volume":"218","author":"A Schafer","year":"2021","unstructured":"Schafer, A. et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J. Exp. Med. 218, e20201993 (2021).","journal-title":"J. Exp. Med."},{"key":"1198_CR25","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","volume":"184","author":"ES Winkler","year":"2021","unstructured":"Winkler, E. S. et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell 184, 1804\u20131820.e16 (2021).","journal-title":"Cell"},{"key":"1198_CR26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41392-021-00759-1","volume":"6","author":"Y Yu","year":"2021","unstructured":"Yu, Y. et al. Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. Sig. Transduct. Target Ther. 6, 346 (2021).","journal-title":"Sig. Transduct. Target Ther."},{"key":"1198_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157\u2013159 (2010).","journal-title":"Nat. Biotechnol."},{"key":"1198_CR28","doi-asserted-by":"publisher","unstructured":"Ni, D. et al. Structural analysis of the spike of the Omicron SARS-COV-2 variant by cryo-EM and implications for immune evasion. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.12.27.474250 (2021).","DOI":"10.1101\/2021.12.27.474250"},{"key":"1198_CR29","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"1198_CR30","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41557-021-00758-3","volume":"13","author":"T Sztain","year":"2021","unstructured":"Sztain, T. et al. A glycan gate controls opening of the SARS-CoV-2 spike protein. Nat. Chem. 13, 963\u2013968 (2021).","journal-title":"Nat. Chem."},{"key":"1198_CR31","doi-asserted-by":"publisher","unstructured":"Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature https:\/\/doi.org\/10.1038\/s41586-022-04441-6 (2022).","DOI":"10.1038\/s41586-022-04441-6"},{"key":"1198_CR32","doi-asserted-by":"publisher","first-page":"105253","DOI":"10.1016\/j.antiviral.2022.105253","volume":"198","author":"R Abdelnabi","year":"2022","unstructured":"Abdelnabi, R. et al. The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. Antivir. Res. 198, 105253 (2022).","journal-title":"Antivir. Res."},{"key":"1198_CR33","doi-asserted-by":"publisher","first-page":"e220446","DOI":"10.1001\/jamaoncol.2022.0446","volume":"8","author":"M Obeid","year":"2022","unstructured":"Obeid, M. et al. Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients. JAMA Oncol. 8, e220446 (2022).","journal-title":"JAMA Oncol."},{"key":"1198_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.24875\/AIDSRev.20000052","volume":"22","author":"AH Mohammed","year":"2020","unstructured":"Mohammed, A. H., Blebil, A., Dujaili, J. & Rasool-Hassan, B. A. The risk and impact of COVID-19 pandemic on immunosuppressed patients: cancer, HIV, and solid organ transplant recipients. AIDS Rev. 22, 151\u2013157 (2020).","journal-title":"AIDS Rev."},{"key":"1198_CR35","doi-asserted-by":"publisher","first-page":"e01828-20","DOI":"10.1128\/JVI.01828-20","volume":"95","author":"C Fenwick","year":"2021","unstructured":"Fenwick, C. et al. Changes in SARS-CoV-2 spike versus nucleoprotein antibody responses impact the estimates of infections in population-based seroprevalence studies. J. Virol. 95, e01828-20 (2021).","journal-title":"J. Virol."},{"key":"1198_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26354-0","volume":"12","author":"P Maisonnasse","year":"2021","unstructured":"Maisonnasse, P. et al. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nat. Commun. 12, 6097 (2021).","journal-title":"Nat. Commun."},{"key":"1198_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19684-y","volume":"11","author":"R Boudewijns","year":"2020","unstructured":"Boudewijns, R. et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nat. Commun. 11, 5838 (2020).","journal-title":"Nat. Commun."},{"key":"1198_CR38","doi-asserted-by":"publisher","first-page":"26955","DOI":"10.1073\/pnas.2014441117","volume":"117","author":"SJF Kaptein","year":"2020","unstructured":"Kaptein, S. J. F. et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc. Natl Acad. Sci. USA 117, 26955\u201326965 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1198_CR39","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","volume":"590","author":"L Sanchez-Felipe","year":"2021","unstructured":"Sanchez-Felipe, L. et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature 590, 320\u2013325 (2021).","journal-title":"Nature"},{"key":"1198_CR40","doi-asserted-by":"publisher","first-page":"733958","DOI":"10.3389\/fimmu.2021.733958","volume":"12","author":"SI Richardson","year":"2021","unstructured":"Richardson, S. I. et al. HIV broadly neutralizing antibodies expressed as IgG3 preserve neutralization potency and show improved Fc effector function. Front. Immunol. 12, 733958 (2021).","journal-title":"Front. Immunol."},{"key":"1198_CR41","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"1198_CR42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jsb.2015.08.007","volume":"192","author":"JL Rubinstein","year":"2015","unstructured":"Rubinstein, J. L. & Brubaker, M. A. Alignment of cryo-EM movies of individual particles by optimization of image translations. J. Struct. Biol. 192, 188\u2013195 (2015).","journal-title":"J. Struct. Biol."},{"key":"1198_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"1198_CR44","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D"},{"key":"1198_CR45","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D"}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01198-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01198-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01198-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:53:46Z","timestamp":1669301626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01198-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1038\/s41564-022-01198-6","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"8 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.F., G.P., P.T. and D.T. are co-inventors on a patent application that encompasses the antibodies and data described in this manuscript (EP 22153464.7 and PCT\/IB2022\/050731). D.T. and G.P. are among the founders of and own equity in Aerium Therapeutics, which has rights to and is pursuing the development of the antibodies described in the publication, and has Sponsored Research Agreements with the Lausanne University Hospital (CHUV) and the Ecole Polytechnique Fe\u0301de\u0301rale de Lausanne (EPFL). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}